

Results of the 2018 Annual Meeting of Shareholders

- **Passing of the resolutions
within the competence of the Ordinary General Meeting**
- **Appointments of Eric Rowinsky and Dimitri Batsis to the Board of Directors**

Second convening notice to the Extraordinary General Meeting on June 4th, 2018

Paris (France), May 16th, 2018, 8pm – BIOPHYTIS (Euronext Growth Paris: ALBPS), a biotechnology company specializing in the development of drug candidates for the treatment of degenerative age-related diseases, announces the approval of all resolutions submitted to shareholders during the Ordinary General Meeting, particularly those related to the appointments of Mr. Eric Rowinsky and Mr. Dimitri Batsis as independent administrators to Biophytis' Board of Directors. The Extraordinary General Meeting could not validly deliberate owing to lack of quorum. Consequently, shareholders are being convened again on June 4th, 2018, to rule on the same agenda.

Biophytis' shareholders met for the combined General Meeting on June 16, 2018. The shareholders present or represented taking part in the vote altogether owned 2,784,761 shares, reaching a quorum of 20.77%, and 4,200,473 voting rights.

Voting Results of the Ordinary General Meeting

The shareholders approved by a very large majority all the resolutions within the competence of the Ordinary General Meeting, including those ratifying the renewal of mandates of Ms. Nadine Coulm, Mr. Jean-G rard Galvez and Mr. Stanislas Veillet, as well as the appointments of Mr. Eric Rowinsky and Mr. Dimitri Batsis as independent administrators of Biophytis for a duration of 3 years.

The ensuing Board meeting that was held at 2:30 pm, following the General Meeting, has reappointed Stanislas Veillet as Chairman.

Eric Rowinsky is a medical doctor focused on the comprehensive development and registration strategies of cancer therapeutics of all types. He also has extensive teaching experience, notably at the Johns Hopkins University School of Medicine. Since 2015, he has served as an Executive Director and

President at Rgenix, a life sciences company focused on discovering new cancer targets using a novel microRNA platform licensed, as well as the Chief Scientific Director of Clearpath Development. He also sits on the Board of Directors or the Scientific Board of several private or listed companies such as Biogen Inc or Fortress Biotech. He is also Editor-in-Chief of *Investigational New Drug* and has published around 315 manuscripts in both the nonclinical and clinical research fields.

Dimitri Batsis is a successful entrepreneur who created in 1987 the web agency Zeni-Corporation, listed on the Paris Stock Exchange and then bought up by Keyrus group in 2007. He then founded Drone Volt, a company specializing in the design, Meeting and commercialization of civilian drones, which has been recording a triple digit growth since 2012. The company, of which he is a shareholder, is listed on Euronext Growth and settled in 30 countries. Dimitri Batsis is today a business angel and Chairman of Dimitri Batsis Investments.

Other key resolutions approved were:

- The social and consolidated accounts for fiscal year 2017
- The allocation of profit for the fiscal year ended December 31, 2017

Full results of votes on resolutions will be available on the Company's website as of May 17th, 2018, in the « Investors / Regulated information » section.

Convening of a new Extraordinary General Meeting on June 4, 2018, with the same agenda

In the absence of a sufficient quorum, resolutions within the competence of the Extraordinary General Meeting could not be put to the vote.

The Board of Directors decided accordingly that a new Extraordinary General Meeting will be held on a second convening on June 4, 2018 at 9.30am at the following address Sorbonne Université, 4 place Jussieu, 75005 Paris, to rule on the same agenda.

Shareholders who would have already casted their votes with the postal voting form or by proxy for the Combined Shareholders' Meeting of May 16th, 2018, do not need to return a new voting form, subject to the conservation of their shares.

Shareholders who attended the Combined General Meeting on May 16, 2018 and who could not attend the next Extraordinary General Shareholders' Meeting on June 4th, 2018 are also invited to send their forms and shareholder certificates within the aforementioned period.

Shareholders who would have not voted by post or proxy as part of the first convening notice are invited to send their forms and shareholder certificates by May 31st, 2018 at the latest.

By post : CACEIS Corporate Trust, Service Assemblées Générales Centralisées - 14, rue Rouget de L'Isle - 92862 ISSY-LES-MOULINEAUX Cedex 9, or via email: ct-assemblies@caceis.com

About BIOPHYTIS

Biophytis SA (www.biophytis.com), founded in 2006, develops drug candidates targeting diseases of aging. Using its technology and know-how, Biophytis has begun clinical development of innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical needs. Specifically, the company is advancing two lead products into mid-stage clinical testing this year: Sarconeos (BIO101) to treat sarcopenic obesity and Macuneos (BIO201) to treat dry age-related macular degeneration (AMD).

The business model of BIOPHYTIS is to ensure the conduct of the project until clinical activity in the patient is proven, then to license the technologies in order to continue the development in partnership with a pharmaceutical laboratory.

Based on the Sorbonne Université campus, Biophytis collaborates with expert scientists from several Sorbonne Université institutes such as the Paris Seine Biology Institute, the Institute of Myology, and the Vision Institute.

BIOPHYTIS is listed on the Euronext Growth market of Euronext Paris (ALBPS; ISIN: FR0012816825).

For more information: <http://www.biophytis.com>

 Follow us on Twitter @biophytis

BIOPHYTIS is eligible for the SMEs scheme



Disclaimer

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Listing Prospectus upon the admission of Company's shares for trading on the regulated market Euronext Growth of Euronext Paris filed with the AMF, which is available on the AMF website (www.amf-france.org) or on BIOPHYTIS' website (www.biophytis.com).

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in BIOPHYTIS in any country. Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company's actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company's prospectus. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall prevail.

BIOPHYTIS
Stanislas VEILLET
CEO
contact@biophytis.com
Tel: +33 (0) 1 44 27 23 00

Citigate Dewe Rogerson
International media & Investors
Laurence BAULT/Antoine DENRY
Laurence.bault@citigatedewerogerson.com
antoine.denry@citigatedewerogerson.com
Tel: +33 (0)1 53 32 84 78
Mob: +33(0)6 64 12 53 61

LifeSci Advisors
Chris MAGGOS
Managing Director, Europe
chris@lifesciadvisors.com
Tel: +41 79 367 6254